Results 231 to 240 of about 146,874 (392)

Development of HER2-specific humanized antibody Herceptin (trastuzumab).

, 2003
Shin-ichi NIHIRA
openalex   +2 more sources

HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: An unexpected effect on TRAIL‐induced apoptosis [PDF]

, 2005
Lenka Zdražilová Dubská, Ladislav Anděra, Michael A. Sheard   +2 more
openalex   +1 more source

Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer. [PDF]

Jpn J Clin Oncol
Kano S, Kiyota N, Kinoshita I, Tada Y, Ijichi K, Yamazaki T, Shimizu Y, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Ito YM, Nishimoto N, Kobayashi K, Isoe T, Noguchi T, Homma A, Dosaka-Akita H.   +17 more
europepmc   +1 more source

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing

International Journal of Cancer, Volume 157, Issue 9, Page 1898-1911, 1 November 2025.
What's new? Fluoropyrimidines, a key component of chemotherapy regimens for a variety of solid tumors, can cause severe toxicity. Patients who have specific genetic variants in the DPYD gene, which encodes an enzyme that inactivates fluoropyrimidines, have increased susceptibility to this toxicity.
Sofía L. J. Peeters, Didier Meulendijks, Zerina Kadric, Sara Ibrovic, Geert‐Jan Creemers, Vanja Milosevic, Matthijs van de Poll, Lieke H. J. Simkens, Birgit A. L. M. Deiman, Hans Gelderblom, Henk‐Jan Guchelaar, Anna M. J. Thijs, Maarten J. Deenen   +12 more
wiley   +1 more source

Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancer [PDF]

, 2005
Gernot Hudelist, Wolfgang J. Köstler, K. Czerwenka, E. Kubista, Johannes Attems, Ruth Melinda Müller, Daphne Gschwantler‐Kaulich, M. Manavi, Isabell Huber, Heinz Hoschützky, Christoph Zielinski, Christian F. Singer   +11 more
openalex   +1 more source

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases. [PDF]

Hum Vaccin Immunother
Zhang X, Liu N, Song S, Zhang C, Li T, Song W, Huang S, Chen Y, Yan W, Zhan J, Wang H, Cui J, Jiang M, Hou H.   +13 more
europepmc   +1 more source

Peptide Tags for Site‐Selective Nonenzymatic Covalent Modification of Proteins

Journal of Peptide Science, Volume 31, Issue 11, November 2025.
Highly selective chemical modification of peptides. This review describes peptide tags that direct covalent chemical modification of proteins. ABSTRACT Bioconjugation chemistry is an important tool for studying proteins, developing pharmaceutical agents, and for many other applications.
Delphine Nørgaard Møller, Christian Kofoed, Mikkel Boas Thygesen, Knud J. Jensen   +3 more
wiley   +1 more source

Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. [PDF]

Ther Adv Med Oncol
You C, Zhang J, Lei J, Fu W, Zheng B, Cai H, Liu M, Li N.   +7 more
europepmc   +1 more source

Should We Advance Our Understanding of Immunoglobulin E in Viral Immunity?

Immunology, Volume 176, Issue 3, Page 312-321, November 2025.
Immunoglobulin E has been extensively studied in allergies and parasitic diseases. Antigen‐specific IgE has been identified as part of the humoral response to viruses. This revision speculates on possible functionalities for IgE, such as neutralisation, cytotoxicity and immunopathology of viral diseases, and provide insights about gaps to fill in ...
Amanda Izeli Portilho, Valéria Oliveira Silva, Luis Fernando de Macedo Brigido, Elizabeth De Gaspari   +3 more
wiley   +1 more source

Breast Cancer: Molecular Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Dysregulation signaling pathways in various breast cancer subtypes and their targeting using different inhibitors. ABSTRACT Breast cancer (BC) is the most prevalent cancer in women and remains the leading cause of cancer‐related mortality globally.
Samad MA, Ahmad I, Khan MR, Suhail M, Zughaibi TA, Al-Abbasi FA, Alhosaini KA, Khan MS, Kumer A, Tabrez S.   +9 more
europepmc   +2 more sources